Law 360

SEPTEMBER 13, 2022

An Ionis Pharmaceuticals Inc. shareholder has lost his bid to delay the Delaware Chancery Court's consideration of a proposed settlement that would resolve derivative claims lodged in litigation over alleged excessive compensation for company directors.

Litigation 40

Litigation Litigating Court 40

Law 360

APRIL 21, 2022

An Ionis Pharmaceuticals Inc. stockholder has sued the company in Delaware's Chancery Court for documents on nonemployee director pay, which he alleged was at one point triple the average of the company's industry peers.

Court 40

Court 40

Law 360

AUGUST 30, 2022

An Ionis Pharmaceuticals Inc. investor is seeking to delay a Delaware Chancery Court hearing to consider a proposed deal to end a suit filed over allegedly excessive company director pay, after being accused by settling parties' counsel of repeatedly trying to derail the settlement process.

Court 40

Court 40

Law 360

AUGUST 9, 2022

An Ionis Pharmaceuticals Inc. investor, represented by Cooch and Taylor PA and Newman Ferrara LLP, is seeking a $475,000 attorney fee award in connection with compensation reforms included in a proposed settlement of a suit he filed over allegedly excessive company director pay.

Attorney 40

Attorney 40

Law 360

JULY 7, 2022

A Delaware vice chancellor has rejected an Ionis Pharmaceuticals Inc. investor's request to consider his bid to consolidate and have his counsel lead litigation filed over allegedly excessive company director pay, saying he can instead challenge an already pending settlement if he so chooses.

Litigation 40

Litigation Litigating 40

Law 360

JUNE 28, 2022

An Ionis Pharmaceuticals Inc. investor is urging a Delaware vice chancellor to consider his bid to consolidate two suits and have his counsel lead litigation filed over allegedly excessive company director pay, arguing that the request should be considered even though a settlement is already pending in one of the suits.

Litigation 40

Litigation Litigating 40